lymphoma

For 30% to 40% of lymphoma patients who receive CAR T therapy, the treatment is a godsend.

The risk of developing lymphoma is slightly elevated in inflammatory bowel disease (IBD) and has increased in recent years in patients with Crohn’s disease.

A new nuclear medicine therapy can cure human non-Hodgkin lymphoma in an animal model.

CAR-T cells are engineered to carry synthetic membrane-spanning receptor molecules that use their outside-facing portion to bind to antigens on cancer cells.

Chemotherapy is a commonly used regimen for cancer treatment, but it is also a double-edged sword.